Genome Canada, Pharma Partners Commit C$33M to Structural Genomics Consortium

NEW YORK (GenomeWeb) – Genome Canada announced today that it has partnered with various pharmaceutical companies to provide C$33 million ($24.6 million) in new funding to the Structural Genomics Consortium (SGC), a public/private group conducting publicly available basic research to advance drug discovery.

According to Genome Canada, it is providing C$11 million to the SGC, with an additional C$5 million coming from the government of Ontario and C$17 million from pharmaceutical partners. The consortium plans to use the funding to continue expanding its open science collaborative network to include disease and patient foundations, partner with clinicians and research hospitals to test its chemical probes on patient samples to help validate new drug targets, and provide training in early-stage drug discovery to young scientists.